Zoledronic Acid Injection
Product Images NDC 68083-256

4 FDA label images from Gland Pharma Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Zoledronic Acid (NDC 68083-256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zoledronic-bag-label (Zoledronic Bag Label)

Zoledronic-bag-label (Zoledronic Bag Label)
Zoledronic Acid Injection 5 mg per 100 mL sterile solution for intravenous infusion by Gland Pharma Limited. The label states the NDC 68083-256-01 and includes usage instructions, storage conditions at 25°C with excursions, and pharmacist dispensing note for a medication guide. It also notes the solution is preservative-free, DEHP-free, and PVC-free.*
FDA Label Image

Zol-image1 (Image01)

Zol-image1 (Image01)
Chemical structure of Zoledronic acid showing a pyrazole ring connected to two phosphonic acid groups, including associated hydroxyl and water moieties.*
FDA Label Image

Zol-image2 (Image02)

Zol-image2 (Image02)
A line graph comparing time to first hip fracture in months between Zoledronic acid 5 mg/100 mL intravenous injection and placebo groups. The x-axis shows months up to 36, and the y-axis indicates cumulative incidence. Two curves represent placebo (dotted line) and Zoledronic acid (solid line) with a stratified log-rank test p-value of 0.0024 indicating statistical analysis.*
FDA Label Image

Zol-image3 (Image03)

Zol-image3 (Image03)
Two bar graphs depict the effects of Zoledronic acid versus Risedronate over time. The first graph shows therapeutic response rates by day, and the second shows serum alkaline phosphatase (SAP) normalization percentages by day. Both graphs indicate higher response and SAP normalization with Zoledronic acid compared to Risedronate, with statistical significance noted (P < 0.001).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.